Drugs / CLN-418
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05306444 | May 2022 → Aug 2024 | neoplasm | Harbour BioMed US, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CLN-418 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05306444 ↗ |
| Route | Intravenous | “Intravenous (IV) administration” NCT05306444 ↗ |